All In Biotech

Drug Trial Radar · NCT05605496

NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies

A Multicenter, Open-label, Proof of Concept Phase II Aiming to Assess the Clinical and Biological Activity of Anti-netrin-1 (NP137) as Add on Therapy in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Immunotherapies

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

57

Actual

Start

Jan 6, 2023

Primary completion

Jan 1, 2027

Study completion Jan 1, 2027

Sponsor

Lead sponsor
Centre Leon BerardAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
NETRIS Pharma
First posted
Nov 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, open-label, proof-of-concept study aiming to assess the clinical and biological impact of NP137 when added to standard PD-1/PD-L1 blockade therapy in 3 independent cohorts of advanced or metastatic solid tumors with various sensitivity to anti-PD-1/PD-L1: * Cohort 1 \[Stable Disease\]: Patients with a radiological documentation of SD according to RECIST V1.1 criteria following at least 12 weeks under standard anti PD-1/PD-L1 therapy. Note: This treatment arm closed on 27/09/2024 due to non-feasibility. * Cohort 2 \[primary refractory\]: Patients with documented radiological PD or short-term SD (\< 6months) according to RECIST V1.1 but with clinical benefit under PD-1/PD-L1 standard therapy. * Cohort 3 \[secondary refractory\]: Patients with documented radiological PD following an initial Objective Response or long-term SD (i.e. ≥6 months) according to RECIST V1.1, with clinical benefit under standard PD-1/PD-L1.

Conditions

  • Advanced Solid Tumors
  • Metastatic Solid Tumors

Interventions

  • NP137Drug

    IV infusion, 14mg/kg, Q3W

  • anti-PD-1/PD-L1Drug

    IV infusion, Q3W or Q6W anti-PD1/PDL1 are standard treatments and are prepared and administred as per respective SmPC and institutional practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR-12W)Time frame: 12 weeks
  2. Progression Free Rate at 12 weeks (PFR-12W)Time frame: 12 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Centre Léon Bérard

    Lyon, France

  • Centre Antoine Lacassagne

    Nice, France

  • Institut Curie

    Paris, France

  • Institut de Cancérologie Strasbourg Europe (ICANS)

    Strasbourg, France

  • Institut Claudius Regaud (IUCT Oncopole)

    Toulouse, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.